(Q34856591)

4 August 2017

1 reference

title

Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experience (English)

1 reference

4 August 2017

1 reference

3

Laurence Klotz

1 reference

4 August 2017

Antonio Hurtado-coll

1

1 reference

4 August 2017

S Larry Goldenberg

series ordinal

2

1 reference

4 August 2017

Martin E Gleave

series ordinal

4

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

60

1 reference

4 August 2017

issue

3 Suppl 1

1 reference

4 August 2017

page(s)

45-51; discussion 51

1 reference

The Incidence and Significance of Detectable Levels of Serum Prostate Specific Antigen After Radical Prostatectomy

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901570-4

7 January 2021

Is Prostate Specific Antigen of Clinical Importance in Evaluating Outcome after Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901570-4

7 January 2021

The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901570-4

7 January 2021

Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901570-4

7 January 2021

Role of Nerve-Sparing Radical Prostatectomy for Clinical Stage B2 Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901570-4

7 January 2021

Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi tumor model

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901570-4

7 January 2021

Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901570-4

7 January 2021

Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901570-4

7 January 2021

Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. The Canadian Urologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901570-4

7 January 2021

CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901570-4

7 January 2021

Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901570-4

7 January 2021

Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901570-4

7 January 2021

Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901570-4

7 January 2021

Resection margin status in radical retropubic prostatectomy specimens: relationship to type of operation, tumor size, tumor grade and local tumor extension

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901570-4

7 January 2021

10.1016/S0090-4295(02)01570-4

Identifiers

DOI

1 reference

4 August 2017

1 reference